Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
12(48%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_2
6
24%
Ph not_applicable
5
20%
Ph phase_3
7
28%

Phase Distribution

0

Early Stage

6

Mid Stage

7

Late Stage

Phase Distribution18 total trials
Phase 2Efficacy & side effects
6(33.3%)
Phase 3Large-scale testing
7(38.9%)
N/ANon-phased studies
5(27.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

12

trials recruiting

Total Trials

25

all time

Status Distribution
Active(14)
Completed(6)
Other(5)

Detailed Status

Recruiting11
Completed6
unknown5
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
12
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (33.3%)
Phase 37 (38.9%)
N/A5 (27.8%)

Trials by Status

completed624%
active_not_recruiting14%
recruiting1144%
not_yet_recruiting28%
unknown520%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT02633553Not Applicable

Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

Recruiting
NCT06692556Phase 3

Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence

Recruiting
NCT07524452Phase 3

Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
NCT06133465

Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management

Completed
NCT06524167

RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer

Recruiting
NCT07371234Phase 2

Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
NCT06897488Phase 2

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

Recruiting
NCT06914440Phase 2

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Recruiting
NCT02395367

Prospective, Observational, Real-world Oral Malignant Tumors Study

Completed
NCT06814067Phase 2

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Not Yet Recruiting
NCT06780059

Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection

Completed
NCT06272214Phase 2

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Recruiting
NCT06313073Not Applicable

Neoadjuvant Radiotherapy for Breast Cancer

Recruiting
NCT04902937

Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.

Recruiting
NCT04989647Phase 3

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy

Recruiting
NCT05445648Phase 2

Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer

Not Yet Recruiting
NCT00860652Not Applicable

Radiotherapy - Adjuvant Versus Early Salvage

Active Not Recruiting
NCT05591456Phase 3

Accelerated Hypofractionated 1 Week Radiotherapy in Breast Cancer Patients

Completed
NCT05460403

Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection

Unknown
NCT04783818

Adjuvant Radiotherapy's Effect on One and Two Stages Prosthetic Breast Reconstruction and on Autologous Reconstruction

Completed

Drug Details

Intervention Type
RADIATION
Total Trials
25